Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification

• Egile Nagusiak: Jintanat Ananworanich (Egilea), Nicolas Chomont (Egilea), James L.K. Fletcher (Egilea), Suteeraporn Pinyakorn (Egilea), Alexandra Schuetz (Egilea), Irini Sereti (Egilea), Rungsun Rerknimitr (Egilea), Robin Dewar (Egilea), Eugene Kroon (Egilea), Claire Vandergeeten (Egilea), Rapee Trichavaroj (Egilea), Nitiya Chomchey (Egilea), Thep Chalermchai (Egilea), Nelson L. Michael (Egilea), Jerome H. Kim (Egilea), Praphan Phanuphak (Egilea), Nittaya Phanuphak (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2015-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and immune activationsss Methods: Thai patients with...